Don't Rely on Omega-3s for Cardiovascular Benefits

January 2021

Do omega-3 fatty acid supplements reduce CV risk?

Mounting evidence suggests they don't...despite prior evidence with Rx Vascepa (icosapent ethyl), a form of EPA (eicosapentaenoic acid).

Vascepa 2 g BID is approved to reduce CV risk in some high-risk patients with moderately elevated triglycerides despite statins.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

COVID-19 Provide Answers About mRNA COVID-19 Vaccines
COVID-19 Put the EUA for Baricitinib Plus Remdesivir in Perspective
COVID-19 Know Who's Eligible for New COVID-19 Monoclonal Antibodies
Education and Training Address Resident Red Flags Early
Substance Use Disorder Be Ready to Manage Anticholinergic Toxicity
New Drugs Prioritize Traditional IV Opioids Over IV Oliceridine
Heart Failure Help Heart Failure Patients Succeed With Med Adherence
Dyslipidemia Don't Rely on Omega-3s for Cardiovascular Benefits
Obesity & Weight Loss Hold Plenity While Patients Are Admitted
IV Medications Stay Alert for Premixes That Should NOT Be Used in Pregnancy